Nutra Pharma has announced that its drug discovery subsidiary, ReceptoPharm, will be introducing its novel antiviral therapy, PEPTERON, at the International AIDS Conference in Vienna, Austria.
Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), Multiple Sclerosis (MS) and Pain, announced today that its drug discovery subsidiary, ReceptoPharm, will be presenting at the International AIDS Conference in Vienna, Austria.
The focus of ReceptoPharm’s presentation will be on its novel antiviral therapy, PEPTERON, which is based on the Company’s leading drug candidate, RPI-MN. RPI-MN has been shown to inhibit the entry of several viruses that are known to cause severe neurological damage in such diseases as encephalitis and HIV. The presentation will be given by Dr. Dorothy Bray, Ph.D., who serves on ReceptoPharm’s Scientific Advisory Board. Previously, Dr. Bray served as the Director of HIV Clinical Development at GlaxoSmithKline (GSK) with global responsibility for their clinical trials program. GSK is currently one of the largest providers of HIV antiretroviral drugs.
“We are pleased to have the opportunity to introduce our antiviral therapy, PEPTERON, at the International AIDS Conference,” commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “As we move forward with our HIV clinical development program, we intend to actively seek out international collaborations and partnerships that will help leverage our ability to bring PEPTERON through the regulatory approval process,” he said.
The International AIDS Conference, which began on July 18 and runs through July 23, 2010, is considered one of the premier conferences for those working in the field of HIV, as well as policy makers, persons living with HIV and other individuals committed to ending the pandemic. The AIDS 2010 program will present new scientific knowledge and offer opportunities for structured dialogue on the major issues facing the global response to HIV.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. Announcing ReceptoPharm’s presentation at the International AIDS Conference in Vienna, Austria, should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.